Epidemiology of liver cancer in South Korea

Bo Hyun Kim; Joong-Won Park

doi:10.3350/cmh.2017.0112

Articles

Page Path

Review

Epidemiology of liver cancer in South Korea

Bo Hyun Kim, Joong-Won Park

Clinical and Molecular Hepatology 2018;24(1):1-9.
Published online: December 18, 2017

DOI: https://doi.org/10.3350/cmh.2017.0112

Center for Liver Cancer, National Cancer Center, Goyang, Korea

Corresponding author : Joong-Won Park Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandonggu, Goyang 10408, Korea Tel: +82-31-920-1605, Fax: +82-31-920-1520 Email: jwpark@ncc.re.kr

• Received: October 27, 2017 • Accepted: November 3, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

24,215 Views
515 Download
165 Web of Science
168 Crossref
161 Scopus

Full Article

Download PDF

ABSTRACT
INTRODUCTION
INCIDENCE OF LIVER CANCER IN KOREA
PREVALENCE OF LIVER CANCER IN KOREA
ETIOLOGY OF HCC IN KOREA
NATURAL HISTORY AND MORTALITY OF HCC IN KOREA
CONCLUSIONS
FOOTNOTES
Abbreviations
REFERENCES

ABSTRACT

Liver cancer is the sixth most common cancer (fourth in men and sixth in women) and the second largest cause of cancer mortality in South Korea. The crude incidence rate of liver cancer was 31.9/100,000 (47.5/100,000 in men and 16.2/100,000 in women) and the age-standardized incidence rate was 19.9/100,000 (32.4/100,000 in men and 8.8/100,000 in women) in 2014. The crude incidence rate increased from 1999 to 2011 and thereafter showed a subtle decreasing tendency. The crude prevalence rate was 113.6/100,000 (170.2/100,000 in men and 57.1/100,000 in women) and the age-standardized prevalence rate was 72.6/100,000 (115.7/100,000 in men and 33.7/100,000 in women) in 2014, which increased from 2010 to 2014. Survival from liver cancer has improved over the last two decades. The 5-year relative survival rate was markedly increased from 10.7% in those diagnosed with liver cancer between 1993 and 1995 to 32.8% in those diagnosed between 2010 and 2014. The epidemiology of liver cancer is influenced by that of underlying liver diseases such as viral hepatitis. Substantial progress has been made in the prevention and treatment of viral hepatitis; however, uncontrolled alcoholic liver disease, obesity and diabetes appears to have the potential to emerge as major causes for liver cancer. Depending on the success of the control of risk factors, the epidemiology of liver cancer in Korea may change.
Keywords: Epidemiology; Hepatocellular carcinoma; Incidence; Liver cancer; Prevalence

INTRODUCTION

Primary liver cancer is the sixth most common cancer and the second largest cause of cancer mortality in the world [1]. The highest incidence rates of liver cancer were observed in Eastern Asia, South-Eastern Asia, Northern Africa and Southern Africa, with China accounting for about 50% of all cases [1]. Approximately 80% of all primary liver cancer is regarded as hepatocellular carcinoma (HCC) [2]. In this review, liver cancer includes all primary liver cancers with disease codes from C22.0 to C22.9 according to the International Classification of Disease codes 10^th edition, since reports from GLOBOCAN, Korea Central Cancer Registry and Korea Statistical Information Service are based on those codes. Otherwise, HCC is considered as the disease code C22.0.

INCIDENCE OF LIVER CANCER IN KOREA

In South Korea, a total of 16,178 cases (12,058 cases in men and 4,120 cases in women) of primary liver cancer were diagnosed in 2014, which ranked sixth after thyroid cancer, stomach cancer, colon and rectal cancer, lung cancer and breast cancer (fourth in men and sixth in women) [3]. The crude incidence rate was 31.9/100,000 (47.5/100,000 in men and 16.2/100,000 in women) and the age-standardized incidence rate (adjusted to the Korea standard population using the mid-year population in 2000) was 19.9/100,000 (32.4/100,000 in men and 8.8/100000 in women) [3]. The age-standardized incidence rate adjusted to the world standard population was 19.4/100,000 (31.4/100,000 in men and 8.6/100,000 in women).

In 2000, 13,126 cases of primary liver cancer (9,898 in men and 3,228 in women) occurred. The crude incidence rate was 27.6/100,000 (41.5/100,000 in men and 13.6/100,000 in women) and the age-standardized incidence rate was 27.6/100,000 (46.1/100,000 in men and 12.1/100,000 in women) [3]. The number of cases and crude incidence rate increased to 16,714 cases and 33.4/100,000 (49.3/100,000 in men and 17.4/100,000 in women) in 2011, and showed a subtle decreasing tendency thereafter (Fig. 1). However, the age-standardized incidence rate declined continuously from 28.9/100,000 in 1999 to 19.9/100,000 in 2014 (Fig. 1). The decreasing incidence rates after adjustment appears attributable to population growth (the mid-year population of South Korea changed from 47,534,124 in 2000 to 50,763,158 in 2014) and increasing proportion of older individuals.

Age- and Sex-specific Incidence

Of 16,178 primary liver cancer cases in 2014, 12,058 were men and 4,120 women with a male-to-female ratio of 2.9:1 [3]. Primary liver cancer was most commonly diagnosed at age 50–59 years (27.3%), followed by 60–69 years (25.2%) and 70–79 years (24.8%). Among women, primary liver cancer was most frequently diagnosed at age 70–79 (32.5%), followed by age 60–69 (23.4%) and age 50–59 (17.3%) years, whereas in men, 30.7% of cases were diagnosed at age 50–59, 25.8% at age 60–69 and 22.2% at age 70–79 years (Fig. 2A). Women were more likely to be diagnosed at older ages compared to men.

Age-specific incidence rates generally declined from 2005 to 2014 over all age groups except for those aged over 80 years (Fig. 2B), even when the number of cases were not decreasing (Fig. 1, 2). When comparing the data from 2005 and 2014, a slight rightshift was observed in the distribution of age at diagnosis (Fig. 2B). Incident cases were most common among those between 50 and 69 years old and were similar for both 2005 and 2014; however, the number of cases diagnosed at age 70 and over increased from 2005 to 2014.

Region-specific Incidence

The incidence of primary liver cancer varied geographically. In 2014, the agestandardized incidence rate was highest in Jeju-do (JJ, 27.4/100,000), followed by Jeollanam-do (JN, 25.7/100,000) and Gyeongsangnam-do (GN, 25.2/100,000) as shown in Fig. 3. A nationwide study indicated higher rates of HBsAg-positivity in Jeju, Jeollanam-do, Gwangju, Busan and Gyeongsangnam-do [4]. Another nationwide survey reported higher rates of anti-hepatitis C virus (HCV) positive tests in Jeollanam-do, Busan, Geyongsangbuk-do and Gyeongsangnam-do [5]. Higher seropositivity might contribute partly to higher incidence of liver cancer; however, other possibilities remain to be elucidated.

PREVALENCE OF LIVER CANCER IN KOREA

Primary liver cancer was the seventh most prevalent cancer after thyroid cancer, stomach cancer, colon and rectal cancer, breast cancer, lung cancer and prostate cancer (5^th in men and 10^th in women) in 2014 [3]. There were 57,691 cases (43,192 men and 14,499 women) who had suffered from primary liver cancer in 2014 [3]. The crude prevalence rate was 113.6/100,000 (170.2/100,000 in men and 57.1/100,000 in women) in 2014 [3]. The age-standardized prevalence rate adjusted to the Korean standard population or the world standard population was 72.6/100,000 (115.7/100,000 in men and 33.7/100,000 in women) or 71.8/100,000 (114.2/100,000 in men and 33.5/100,000 in women), respectively [3].

The number of prevalent cases increased from 43,351 in 2010 to 57,691 in 2014 and so had the age-standardized prevalence rate (adjusted to the Korean standard population) from 63.4 in 2010 to 72.6 in 2014 (Fig. 4). The increased prevalence despite decreased incidence of primary liver cancer may be explained by prolonged survival of patients, since prevalence is influenced by both the incidence rate and the average duration of the disease.

Age- and Sex-specific Prevalence

Of 57,691 primary liver cancer prevalent cases in 2014, 43,192 were men and 14,499 women with a male-to-female ratio of 3.0:1 [3]. Primary liver cancer occurred most commonly between age 60–69 years (32.0%), followed by 50–59 years (29.3%) and 70–79 years (22.8%). Primary liver cancer in female patients was most common in the age group 60–69 years, followed by 70–79 years (29.5%) and 50–59 years (21.7%), whereas primary liver cancer in male patients was most common in the age group 60–69 years (32.4%), followed by 50–59 years (29.3%) and 70–79 (22.8%) years. Female patients tended to be older than male patients were, as shown in incidence trends (Fig. 2A and 5A).

The highest age-specific prevalence rates were observed between 55 and 64 years in both 2010 and 2014 (Fig. 5B). Age-specific prevalence rates increased substantially from 2010 to 2014 in those aged over 55 years.

ETIOLOGY OF HCC IN KOREA

Hepatitis B virus

Hepatitis B virus (HBV) is the predominant etiology of HCC in Korea as well as in China and Taiwan [6]. According to several retrospective studies, HBV accounted for 62~75% of HCC (Table 1) [7-11]. The prevalence rates of HBV infection ranged from 8–10% in the 1980s and early 1990s [12]. As the national immunization program for HBV was implemented in 1995, the prevalence decreased to 2.9% in 2013. According to the Korean National Health and Nutrition Examination Survey in 2014, the age-specific prevalence among those aged 10–19 years and those aged 20–29 years were < 1% and < 2%, respectively, and males aged 30–59 years and females aged 60–69 years had a prevalence of 4–5% and 4%, respectively [12]. Therefore, the prevalence of HBV infection is anticipated to continue to decrease. Taiwanese studies have demonstrated that the HCC incidence rate declined in children who had been immunized at birth compared to non-immunized children from the pre-universal immunization era. Given that liver cancer generally occurs in middle-aged or elderly adults and the national immunization program was implemented in 1995, the decreasing tendency of HBV infection does not appear to have affected the incidence or prevalence of HCC to a larger degree yet.

Antiviral therapy has been shown to significantly reduce the risk of HCC [13]. Nucleos(t)ide analogues have been introduced with restrictions for financial reimbursement since 1999; however, patients have been able to get a life-long reimbursement since 2010. During that period, the number of patients treated with nucleos(t) ide analogues increased exponentially [14].

Hepatitis C virus

Although HCV is the main cause of HCC in Japan, North America and Europe, it accounts for approximately 10% of HCC cases in Korea [6-11,15]. The prevalence of HCV infection based on anti-HCV positivity was 0.7% in 2014 [16]. No prophylactic vaccine is currently available for HCV; however, the virus can be eliminated by antiviral therapy. New direct-acting antiviral agents have shown excellent outcomes of over 90–95% of sustained virological response [17]. Achieving sustained virological response has been demonstrated to decrease the risk of HCC [18]. In Korea, users of direct-acting antiviral agents have been reimbursed, thus these agents have become utilized to a wider extent since August 2015. Promising results are anticipated; however, the actual influence of antiviral therapy on the incidence of HCC has not been established yet.

Etiologies other than hepatitis virus

Heavy alcohol consumption contributes to the development of HCC, per se , and increases the risk of developing HCC in patients with HBV or HCV infection [19,20]. In Korea, 2.4–10.9% of HCC has been attributed to alcohol use [6,7,9-11]. A prospective observational study reported that 67% of Korean patients newly diagnosed with HCC had a past or current history of alcohol abuse [6]. According to a World Health Organization report on alcohol and health, prevalence of episodic heavy drinking (defined as consumption of at least 60 grams or more of pure alcohol on at least one occasion in the past 30 days) was 12.1% and 0.1% in males and females, respectively, aged 15 years or more [21]. Korean adults above 15 years of age drink an average of 12.3 liters of pure alcohol per year, which translates to 26.7 grams per day [21]. This average consumption remained the same when compared between the years 2008–2010 and the years 2003–2005.

Data are scarce in Korea, however, HCC cases from etiologies other than HBV, HCV, or alcohol ranged from 6.8–15.1% [7,9,11,22]. Nonalcoholic fatty liver disease-associated HCC falls in this category. Nonalcoholic fatty liver disease is considered to be a higher risk factor in North America and Europe than in Asian countries [6]. Since Korea is a HBV-endemic area, prior HBV infection is considered to play a role even in the development of cryptogenic HCC [22]. A recent study reported that 82.1% of patients were positive for anti-HBc in serum and 52.6% were positive for both anti-HBc in serum and HBV DNA in the liver tissue among 78 patients who underwent resection or transplantation for cryptogenic HCC [23].

Diabetes and/or obesity increases the risk of developing HCC and they are closely associated with nonalcoholic fatty liver disease [19]. The prevalence of diabetes and obesity is increasing, and the age-standardized prevalences of diabetes and obesity (body mass index of 25 kg/m² or higher) in Korean adults were 11.0% and 31.8%, respectively [24]. Recent studies reported that diabetes was found in 21.8–37.1% of Korean patients with cryptogenic HCC [11,23]. It is of concern that nonalcoholic fatty liver disease-associated HCC can also develop in a non-cirrhotic liver [23]. Although a retrospective study showed that the proportion of HCC being based on nonalcoholic fatty liver disease without anti-HBc positivity increased from 3.8% in the years 2001–2005 to 12.2% in the years 2006–2010 [22], further studies are warranted.

NATURAL HISTORY AND MORTALITY OF HCC IN KOREA

According to recent reports on HCC, mean ages were above 55 years and about 80% were male at the time of diagnosis [7-10]. Approximately 60% or more of patients had preserved liver function (Child-Turcotte-Pugh class A). A substantial proportion of patients with HCC are diagnosed at an advanced stage. More than 35% of patients had Barcelona Clinic Liver Cancer C or D stage tumors at the time of diagnosis [7-10]. Transarterial therapies remain the mainstay of treatment modalities [8-10].

The Annual Report of Cancer Statistics has shown the survival gain of primary liver cancer over the last two decades [3]. For those who had been diagnosed with liver cancer between 2010 and 2014, the 5-year relative survival rate was markedly increased from 10.7% to 32.8% compared with those who had been diagnosed between 1993 and 1995 (Fig. 6) [3].

A nationwide observational study also demonstrated a significant improvement in overall survival of patients with HCC diagnosed between 2008 and 2010 relative to those diagnosed between 2003 and 2005 even after adjustment for confounding factors [8]. Age-adjusted analysis indicated the improvement of the median survival time from 17.2 months to 28.4 months and 5-year survival rate from 35% to 45%. It is noteworthy that the survival improvement was remarkable in HBV-related HCC, which coincided with the exponential use of oral antiviral agents for HBV [8,9]. Nonetheless, the disease burden of liver cancer does not appear to have decreased yet [14]. A recent study suggested that widespread use of antiviral agents for HBV might increase the number of patients at risk of developing liver cancer as well as the individual’s life expectancy while decreasing the mortality from underlying liver disease [14].

Based on the mortality data from the Korean Statistical Information Service, the crude mortality rate from primary liver cancer was 22.8/100,000 in 2014 (34.0/100,000 in men and 11.6/100,000 in women) and remained stable throughout the last decade (Fig. 7) [25]. Of all cancer mortalities in 2014, it was the second most common cause across all ages following lung cancer, and the most common cause in the fifth and sixth decades of life. The age-standardized mortality rate (adjusted to the mid-year population of 2005 in Korea) was 16.4/100,000 (27.4/100,000 in men and 6.9/100,000 in women) in 2014, decreasing from 22.3/100,000 (37.6/100,000 in men and 9.7/100,000 in women) in 2005 [25]. The discrepancy between crude rate and age-adjusted rate can be observed as with the incidence rate. The age-specific mortality rates increase with age; however, it is of note that a substantial proportion of patients with liver cancer die at a younger age when compared with those with any other type of cancer (Fig. 8).

CONCLUSIONS

Liver cancer mostly occurs as a complication of underlying liver disease such as viral hepatitis; therefore, the epidemiology of liver cancer is influenced by that of underlying disease. Substantial progress has been made in the prevention and treatment of viral hepatitis and this is expected to affect the epidemiology of liver cancer currently or in the near future. Temporal improvement in overall survival from liver cancer has been demonstrated. However, liver cancer is still the sixth most common cancer and the second largest cause of all cancer mortalities in Korea. Currently, crude incidence rates are stable and prevalence rates are increasing while age-adjusted incidence rates are decreasing. Considering that the disease burden correlates with crude rates of the disease for a given population [26,27]. a careful approach should be taken.

FOOTNOTES

Authors’ contribution

BH Kim and JW Park were responsible for the acquisition, analysis, and interpretation of the data, and the drafting of the manuscript.

Financial support

This work was supported by the National Cancer Center, Korea (#1510520).

Conflict of Interest

The authors have no conflicts to disclose.

Figure 1.

Trends in primary liver cancer incidence. Dark grey columns and light grey columns represent the number of male and female incident cases, respectively (left axis). Solid symbols indicate crude incidence rates and hollow symbols indicate age-standardized incidence rates (right axis).

Figure 2.

Age-specific incidence of liver cancer. (A) Dark grey columns and light grey columns represent the number of male and female incident cases in 2014, respectively (left axis). The black solid line indicates the age-specific incidence rates while the dark grey dashed line and light grey dotted line indicate age-specific incidence rates in males and females, respectively (right axis). (B) Light grey columns and dark grey columns represent the number of cases diagnosed in 2005 and 2014, respectively (left axis). Solid symbols and hollow symbols indicate age-specific incidence rates in 2005 and 2014, respectively (right axis).

Figure 3.

Crude and age-standardized incidence of liver cancer by region. Light grey columns and dark grey columns represent crude incidence rates in 2005 and 2014, respectively. Solid symbols and hollow symbols indicate age-standardized incidence rates in 2005 and 2014, respectively. SU, Seoul; BS, Busan; DG, Daegu; IC, Incheon; GJ, Gwangju; DJ, Daejeon; US, Ulsan; SJ, Sejong; GG, Gyeonggi-do; GW, Gangwon-do; CB, Chungcheongbuk-do; CN, Chungcheongnam-do; JB, Jeollabuk-do; JN, Jeollanam-do; GB, Gyeongsangbuk-do; GN, Gyeongsangnam-do; JJ, Jeju-do.

Figure 4.

Trends in prevalence of primary liver cancer. Dark grey columns and light grey columns represent the number of male and female prevalent cases, respectively (left axis). Solid symbols indicate crude prevalence rates and hollow symbols indicate age-standardized prevalence rates (right axis).

Figure 5.

Age-specific prevalence of liver cancer. (A) Dark grey columns and light grey columns represent the number of male and female prevalent cases in 2014, respectively (left axis). The black solid line indicates the age-specific prevalence while the dark grey dashed line and light grey dotted line indicate age-specific prevalence rates of males and females, respectively (right axis). (B) Light grey columns and dark grey columns represent the number of prevalent cases in 2010 and 2014, respectively (left axis). Solid symbols and hollow symbols indicate age-specific prevalence rates in 2010 and 2014, respectively (right axis).

Figure 6.

Trends in primary liver cancer survival. Light grey columns and dark grey columns denote 5-year relative survival rates (the ratio of survival rates of individuals who were diagnosed with liver cancer to those who were not) and 10-year relative survival rates, respectively.

Figure 7.

Trends in liver cancer mortality rates. Dark grey columns and light grey columns represent the number of male and female mortality cases from liver cancer, respectively (left axis). Solid symbols indicate crude mortality rates and hollow symbols indicate age-standardized mortality rates (right axis).

Figure 8.

Age distribution of cancer mortality. The upper bar represents percentages of mortality cases from all-sites cancers and the lower bar represents those of mortality cases from liver cancer according to the ages.

Table 1.

Clinical characteristics of patients diagnosed with hepatocellular carcinoma

Table 1.
	Number	Period	Data source	Age/Sex	Etiology	Child-Turcotte-Pugh class	BCLC stage	Treatment
Kim, et al. [7] (2012)	1717	2003–2008	Single hospital	57.0 yr (median)	HBV (72.1%)	A (77.1%)	0 (9.8%)
				Male (80.3%)	HCV (10.4%)	B (19.7%)	A (30.6%)
					Alcohol (2.4%)	C (3.2%)	B (19.4%)
							C (35.4%)
							D (4.8%)
Kwak, et al. [9] (2014)	1972	2004–2009	Single hospital	56.0 yr (median)	HBV (74.6%)	A (81.6%)	0 (4.7%)	Resection (1.5%)
				Male (81.6%)	HCV (9.3%)	B (16.7%)	A (19.8%)	Local ablation (3.5%)
					Alcohol (7.4%)	C (1.7%)	B (9.3%)	Transplantation (1.5%)
							C (64.4%)	Transarterial therapy (58.3%)
							D (1.8%)	Radiotherapy (5.0%)
								Systemic therapy (5.7%)
								Supportive care (7.4%)
Lee, et al. [10] (2017)	2211	2004–2013	Three hospitals	58.3 yr	HBV (68.9%)	A (59.3%)	0 (13%)	Resection (13.4%)
				Male (79.5%)	HCV (11.6%)	B (29.7%)	A (33%)	Local ablation (19.2%)
					Alcohol (10.9%)	C (11.0%)	B (12%)	Transplantation (0.5%)
							C (29%)	Transarterial therapy (46.0%)
							D (13%)	Systemic therapy (4.7%)
							D (13%)	Supportive care (16.1%)
Kim, et al. [8] (2017)	4515	2003–2005	Population-based national cancer registry	57.2 yr	HBV (62.5%)	A (64.2%)	0 (7.2%)	Resection (9.7%)
				Male (81.1%)	HCV (9.9%)	B (26.9%)	A (47.0%)	Local ablation (7.1%)
						C (8.8%)	B (10.4%)	Transplantation (0.7%)
							C (26.6%)	Transarterial therapy (53.4%)
							D (8.8%)	Systemic therapy (0.8%)
								Radiotherapy (1.1%)
								Supportive care (27.2%)
	4582	2008–2010		59.4 yr	HBV (62.2%)	A (71.6%)	0 (8.1%)	Resection (15.6%)
				Male (77.9%)	HCV (10.4%)	B (23.4%)	A (41.5%)	Local ablation (11.0%)
						C (5.0%)	B (11.3%)	Transplantation (0.7%)
							C (33.0%)	Transarterial therapy (46.1%)
							D (6.2%)	Systemic therapy (4.1%)
								Radiotherapy (1.3%)
								Supportive care (21.2%)

HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer.

Abbreviations

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
Article
PubMed
2. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-238.
PubMed
PMC
3. Korea Central Cancer Registry; National Cancer Center. Annual report of cancer statistics in Korea in 2014. Ministry of Health and Welfare 2016.
4. Lee BS, Cho YK, Jeong SH, Lee JH, Lee D, Park NH, et al. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. J Med Virol 2013;85:1327-1333.
Article
PubMed
5. Kim DY, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586-594.
Article
PubMed
PDF
6. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-2166.
PubMed
PMC
7. Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-1127.
PubMed
8. Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, et al. Temporal Improvement in Survival of Patients with Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Population. J Gastroenterol Hepatol 2017 Jun 14;[Epub ahead of print].
9. Kwak HW, Park JW, Nam BH, Yu A, Woo SM, Kim TH, et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2014;29:820-829.
PubMed
10. Lee YS, Seo YS, Kim JH, Lee J, Kim HR, Yoo YJ, et al. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut Liver 2017 Sep 7;[Epub ahead of print].
Article
PubMed
PMC
PDF
11. Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 2013;13:335.
Article
PubMed
PMC
PDF
12. Cho EJ, Kim SE, Suk KT, An J, Jeong SW, Chung WJ, et al. Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol 2017;23:205-211.
Article
PubMed
PMC
PDF
13. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.
Article
PubMed
14. Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology 2017;66:1454-1463.
Article
PubMed
PDF
15. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
Article
PubMed
16. Kim BK, Jang ES, Kim JH, Park SY, Ahn SV, Kim HJ, et al. Current status of and strategies for hepatitis C control in South Korea. Clin Mol Hepatol 2017;23:212-218.
Article
PubMed
PMC
PDF
17. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-194.
Article
PubMed
18. Ioannou GN, Green PK, Berry K. HCV eradication induced by directacting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017 Sep 5;[Epub ahead of print].
Article
PubMed
PMC
19. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014;60:1767-1775.
Article
PubMed
PMC
20. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47(Suppl):S2-S6.
PubMed
PMC
21. World Health Organization. Global status report on alcohol and health. Switzerland: Management of Substance Abus; 2014.
22. Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, Kim YJ, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84(Suppl 1):17-22.
Article
PubMed
PDF
23. Shim CW, Park JW, Kim SH, Kim JS, Kim BH, Kim SH, et al. Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. Therap Adv Gastroenterol 2017;10:529-536.
Article
PubMed
PMC
PDF
24. Ha KH, Kim DJ. Trends in the Diabetes Epidemic in Korea. Endocrinol Metab (Seoul) 2015;30:142-146.
Article
PubMed
PMC
25. Statistics Korea. Korean Statistical Information Service. 2017.
26. Abello J, Cormode G. Discrete Methods in Epidemiology. American Mathematical Society 2007;1-260.
27. Schottenfeld D, Fraumeni J. Cancer Epidemiology and Prevention. Oxford University Press, 2006.

Figure & Data

References

Citations

Citations to this article as recorded by

Projected cancer burden attributable to population aging: Insight from a rapidly aging society
Minh‐Thao Tu, Hoejun Kwon, Yoon‐Jung Choi, Hyunsoon Cho
International Journal of Cancer.2026; 158(4): 951. CrossRef
Global, regional, and national burden and trends of liver cancer due to hepatitis B in young adults from 1990 to 2021 and forecast to 2030: insights from the Global Burden of Disease Study 2021
Jinbo Li, Yaling Li, Bihong Ke, Xiaosheng Zhang, Weigang Wang, Yandi Li, Jia Lian, Tian Yao, Keke Wang, Suping Wang, Yongliang Feng
Internal and Emergency Medicine.2026; 21(1): 69. CrossRef
Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma
Kyle R Stephens, Megan Wilson, Manting Xu, Jeremy T Gaskins, Gina Genova, Robert C G Martin II
World Journal of Gastroenterology.2026;[Epub] CrossRef
Burden of hepatitis B virus-associated liver cancer in Asia: findings from the global burden of disease study
Xin-Jing Yang, Xue-Qi Yang, Xuan-Ying Mo, Jing Zuo, Yu-Chen Fan
Frontiers in Public Health.2026;[Epub] CrossRef
Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration
Hao Ying, Yuhao Pan, Xingyu Zhu, Qijia Xuan
Frontiers in Immunology.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Fibrosis 5 Score and the Risk of Liver-Related Events in the General Population
Byeong Geun Song, Goeun Park, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Gut and Liver.2026; 20(4): 645. CrossRef
GAFAD: A liquid chromatography-tandem mass spectrometry-based model for early hepatocellular carcinoma detection beyond GALAD’s limitations
Hyojin Kim, Wonseok Oh, Juri Park, Saeyoung Lee, Won Suk Yang, Soon Sun Kim, Jae Youn Cheong, Je-Hyun Baek
Clinical and Molecular Hepatology.2026; 32(3): 1225. CrossRef
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
Molecular and Cellular Biochemistry.2025; 480(2): 1225. CrossRef
Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
Youngju Song, Jinhong Jung, Jin‐hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sang Min Yoon
Journal of Medical Imaging and Radiation Oncology.2025; 69(1): 144. CrossRef
Hip fracture and cancer: descriptive epidemiological study demonstrating a paradigm shift in common orthopedic trauma
Juri Teramoto, Yasuhiro Homma, Taiji Watari, Koju Hayashi, Tomonori Baba, Nobuhiko Hasegawa, Daisuke Kubota, Tatsuya Takagi, Muneaki Ishijima
Journal of Joint Surgery and Research.2025; 3(1): 17. CrossRef
Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy
Weijia Wang, Behishta Hashimi, Ping Wang
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(6): 6335. CrossRef
A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease
Byeong Geun Song, GoEun Park, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Journal of Gastroenterology and Hepatology.2025; 40(4): 979. CrossRef
Risk of ischemic stroke in korean patients with Cancer: Insights from national health insurance data
Juwang Moon, Ji Min Rhyu, Choyun Jeong, Seung Jae Lee, Jong Seung Kim, Hyun Goo Kang
Journal of Stroke and Cerebrovascular Diseases.2025; 34(5): 108281. CrossRef
Molecular Targets of Plant-based Alkaloids and Polyphenolics in Liver and Breast Cancer- An Insight into Anticancer Drug Development
Salma Batool, Laiba Asim, Fawad Raffaq Qureshi, Ammara Masood, Maria Mushtaq, Rahman Shah Zaib Saleem
Anti-Cancer Agents in Medicinal Chemistry.2025; 25(5): 295. CrossRef
Mortality Risk According to Changes in Alcohol Consumption Post‐Diagnosis Among Liver Cancer Patients
Thi Tra Bui, Eunjung Park, Hee‐Yeon Kang, Byungmi Kim, Young‐Joo Won, Jin‐Kyoung Oh
Liver International.2025;[Epub] CrossRef
Time-trend costs of infection-related cancers in Japan: a systematic review
Trinh Xuan Thi Nguyen, Sumeet Lal, Sulemana Abdul-Salam
Discover Public Health.2025;[Epub] CrossRef
Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Clinical and Molecular Hepatology.2025; 31(2): 509. CrossRef
Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for hepatitis B virus-related hepatocellular carcinoma
Ke-Gong Xiong, Tai-Shun Lin, Qing-Biao Lin, Jin-Feng Kong, Kun-Yu Ke
Scientific Reports.2025;[Epub] CrossRef
Changes in antiviral treatment rate for hepatitis B virus before hepatocellular carcinoma diagnosis: a nationwide Korean study
Young Eun Chon, Jonghyun Lee, Eileen L. Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Development and Effectiveness of a Clinical Decision Support System for Postembolization Syndrome after Transarterial Chemoembolization: A Randomized Controlled Trial
Myoung Soo Kim, Minkyeong Kang
Asian Nursing Research.2025; 19(3): 291. CrossRef
Metabolomic comparative study in patients with liver cirrhosis and hepatocellular carcinoma related to hepatitis B virus infection
Yanping Wang, Huan Wang, Shuai Wei, Zhiliang Gao, Haili Gao, Xinwei Wang, Haijun Liang, Daokun Yang
European Journal of Gastroenterology & Hepatology.2025; 37(9): 1040. CrossRef
Combining serologic biomarkers with the PAGE B score improves risk stratification for hepatocellular carcinoma development among chronic hepatitis B patients
Michael Stec, Mark Anderson, Mary A. Rodgers, Tiffany Fortney, Danny Ka-Ho Wong, Lung-Yi Mak, Man-Fung Yuen, Gavin A. Cloherty
Scientific Reports.2025;[Epub] CrossRef
Non-Viral Hepatocellular Carcinoma with Normal Alpha-Fetoprotein but Elevated CA19-9 in an Older Patient with Obesity: A Case Report
Seung Hun Lee, Mi Soo Kim, Jeong Gyu Lee
Korean Journal of Geriatrics & Gerontology.2025; 26(3): 147. CrossRef
Blocking the E2F transcription factor 1/high-mobility group box 2 pathway enhances the intervention effects of α-santalol on the malignant behaviors of liver cancer cells
Hui Wang, Min Tang, Erli Pei, Ying Shen, Aili Wang, Moubin Lin
The International Journal of Biochemistry & Cell Biology.2024; 168: 106516. CrossRef
Non-metastatic hip fractures surgery in patients with active cancer: benefit and risk
Juri Teramoto, Yasuhiro Homma, Taiji Watari, Koju Hayashi, Tomonori Baba, Nobuhiko Hasegawa, Daisuke Kubota, Tatsuya Takagi, Muneaki Ishijima
International Orthopaedics.2024; 48(4): 1089. CrossRef
The perioperative experience and needs of hepatocellular carcinoma patients in interventional therapy: a phenomenological qualitative study
Ling Li, Hua-Zhen Zhang, Yan Ge, Ya-Li Rao, Ting Liu, Miao-Miao Guo, Shu-Ping Xiao
European Journal of Gastroenterology & Hepatology.2024; 36(4): 423. CrossRef
Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3
Liu-Xia Yuan, Mei Luo, Ruo-Yu Liu, Hui-Xuan Wang, Lin-Ling Ju, Feng Wang, Ya-Li Cao, Zhong-Cheng Wang, Lin Chen
BMC Cancer.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
Yuri Cho, Bo Hyun Kim, Young-Suk Lim
Digestive Disease Interventions.2024; 08(03): 169. CrossRef
TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma
Shubin Zhang, Zhongyi Jiang, Pusen Wang, Weihao Jiang, Wei Ding, Lin Zhong
Discover Oncology.2024;[Epub] CrossRef
Comprehensively analysis of IL33 in hepatocellular carcinoma prognosis, immune microenvironment and biological role
Lifang Wei, Ping He, Zhongqiu Tan, Cheng Lin, Zhongheng Wei
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clinical and Molecular Hepatology.2024; 30(3): 345. CrossRef
Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications
Yu Zhang, Weihao Xu, Chuanhui Peng, Shenli Ren, Cheng Zhang
Journal of Translational Medicine.2024;[Epub] CrossRef
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
Kyu-Pyo Kim, Kang Mo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Won Chul Cha, Mira Kang, Dong Hyun Sinn, Myung Ji Goh, Do Young Kim, Min Ji Lee, Subin Lim, DongKyu Kim, Kyoungdae Baek, Joohyun Kim, Eui Jun Choi, Doik Lee, Jung-Ae Kim, Ki-Hun Kim
Liver Cancer.2024; : 1. CrossRef
Targeting the p53-p21 axis in liver cancer: Linking cellular senescence to tumor suppression and progression
Lakshmi Thangavelu, Abdulmalik S.A. Altamimi, Nehmat Ghaboura, M. Arockia Babu, R. Roopashree, Pawan Sharma, Pusparghya Pal, Chhavi Choudhary, G.V. Siva Prasad, Aashna Sinha, Ashok Kumar Balaraman, Sushama Rawat
Pathology - Research and Practice.2024; 263: 155652. CrossRef
Genome-Wide Association Study to Identify Genetic Factors Linked to HBV Reactivation Following Liver Transplantation in HBV-Infected Patients
Joonhong Park, Dong Yun Kim, Heon Yung Gee, Hee Chul Yu, Jae Do Yang, Shin Hwang, YoungRok Choi, Jae Geun Lee, Jinsoo Rhu, Donglak Choi, Young Kyoung You, Je Ho Ryu, Yang Won Nah, Bong-Wan Kim, Dong-Sik Kim, Jai Young Cho, The Korean Organ Transplantation
International Journal of Molecular Sciences.2024; 26(1): 259. CrossRef
Experience of Lifetime Health Maintenance Program: An Observational Study of a 30-Year Period of Outpatient Primary Care in a Tertiary Hospital
Seo Young Kang, Young Sik Kim
Korean Journal of Family Medicine.2023; 44(5): 281. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful
Walaa Abdelhamed, Mohamed El‐Kassas
Journal of Viral Hepatitis.2023; 30(2): 148. CrossRef
Nurses' comfort care of transarterial chemoembolization patients based on their perceptions around postembolization syndrome and symptom interference
Myoung Soo Kim, Minkyeong Kang, Jiwon Park, Jung Mi Ryu
Nursing Open.2023; 10(5): 2877. CrossRef
Disparities in stage at diagnosis for liver cancer in China
Tianhao Shan, Xianhui Ran, Huizhang Li, Guoshuang Feng, Siwei Zhang, Xuehong Zhang, Lei Zhang, Lingeng Lu, Lan An, Ruiying Fu, Kexin Sun, Shaoming Wang, Ru Chen, Li Li, Wanqing Chen, Wenqiang Wei, Hongmei Zeng, Jie He
Journal of the National Cancer Center.2023; 3(1): 7. CrossRef
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly
Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 120. CrossRef
Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
Jaehyeon Lee, Seung Yeob Lee, Yong Gon Cho, Dal Sik Kim, Joonhong Park
Medicina.2023; 59(3): 443. CrossRef
Sodium-glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients With Type 2 Diabetes
Sungho Bea, Han Eol Jeong, Jae Hyeon Kim, Oriana Hy Yu, Laurent Azoulay, Ju-Young Shin
Clinical Gastroenterology and Hepatology.2023; 21(13): 3451. CrossRef
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef
Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy
Yirong Liu, Brian Chou, Amulya Yalamanchili, Sara N. Lim, Laura A. Dawson, Tarita O. Thomas
Journal of Clinical Medicine.2023; 12(10): 3517. CrossRef
Xiaoaiping injection affects the invasion and metastasis of hepatocellular carcinoma by controlling AFP expression
Shu Huang, Ganxin Wang
Oncology and Translational Medicine.2023; 9(1): 35. CrossRef
Role of Genetic Polymorphism and Expression of Angiopoietin-2 in Patients with Primary Liver Cancer Among the Southeastern Chinese Hans Population
Bin Wang, Yunxiao Lv, Shenjian Ye, Jin Zhao, Xinling Pan
Genetic Testing and Molecular Biomarkers.2023; 27(6): 193. CrossRef
Operational Definition of Liver Cancer in Studies Using Data from the National Health Insurance Service: A Systematic Review
Yu Rim Kim, Ji Yoon Baek, Seung Hee Seo, Hyeree Park, Sooyoung Cho, Aesun Shin
Journal of Cancer Prevention.2023; 28(2): 47. CrossRef
A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly
Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park
Scientific Reports.2023;[Epub] CrossRef
New-onset dyslipidemia in adult cancer survivors from medically underserved areas: a 10-year retrospective cohort study
Yun Hwa Jung, IL Yun, Eun-Cheol Park, Sung-In Jang
BMC Cancer.2023;[Epub] CrossRef
Impact of hepatitis B virus infection on the risk of gallbladder polyps: a cohort study
Nam Hee Kim, Hong Joo Kim, Ji Hun Kang
The Korean Journal of Internal Medicine.2023; 38(6): 844. CrossRef
A systematic review and meta-analysis of blood transfusion rates during liver resection by country
Seonju Kim, Yun Kyung Jung, Kyeong Geun Lee, Kyeong Sik Kim, Hanjun Kim, Dongho Choi, Sumi Lee, Boyoung Park
Annals of Surgical Treatment and Research.2023; 105(6): 404. CrossRef
The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults
Jisuk Yun, Soon-Chan Kwon
Toxics.2023; 11(12): 965. CrossRef
hsa_circ_0002980 prevents proliferation, migration, invasion, and epithelial-mesenchymal transition of liver cancer cells through microRNA-1303/cell adhesion molecule 2 axis
Yu Wang, Zhenlin Li, Jun He, Wenxiang Chen, Yiming Li, Xiangmei Chen, Junjie Liang, Qiangfeng Yu, Jianyin Zhou
Aging.2023; 15(24): 14915. CrossRef
Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B
Hye Yeon Chon, Jae Seung Lee, Hye Won Lee, Ho Soo Chun, Beom Kyung Kim, Won Young Tak, Jun Yong Park, Young-Oh Kweon, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Soo Young Park, Seung Up Kim
Clinical Gastroenterology and Hepatology.2022; 20(4): e794. CrossRef
Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Digestive Diseases and Sciences.2022; 67(9): 4565. CrossRef
Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea
Diego Novick, Jae Min Cho, Sam Colman, Agota Szende
Drugs - Real World Outcomes.2022; 9(2): 263. CrossRef
Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications
Nguyen H. Tran
Current Oncology Reports.2022; 24(2): 187. CrossRef
Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study
Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
BMC Medicine.2022;[Epub] CrossRef
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Jihyun An, Hyung-Don Kim, Seon-Ok Kim, Ha Il Kim, Gi-Won Song, Han Chu Lee, Ju Hyun Shim
Clinical and Molecular Hepatology.2022; 28(1): 67. CrossRef
Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
BMC Cancer.2022;[Epub] CrossRef
Association Between Environmental and Socioeconomic Risk Factors and Hepatocellular Carcinoma: A Meta-Analysis
Wenfeng Lu, Fengjiao Zheng, Zhi Li, Rui Zhou, Lugang Deng, Wenwei Xiao, Wenyan Chen, Rong Zhao, Yulan Chen, Yuxing Tan, Zhibo Li, Limin Liu, Duxun Tan, Nan Liu
Frontiers in Public Health.2022;[Epub] CrossRef
Midazolam Suppresses Hepatocellular Carcinoma Cell Metastasis and Enhances Apoptosis by Elevating miR-217
Qian Shen, Yanqiong Xia, Leilei Yang, Bo Wang, Jian Peng, Min Tang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma
Mizelle D'Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
Surgical Oncology.2022; 41: 101730. CrossRef
Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts
Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari
PLOS ONE.2022; 17(3): e0265668. CrossRef
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
BMC Gastroenterology.2022;[Epub] CrossRef
Changing epidemiology of hepatocellular carcinoma in Asia
Chen‐hao Zhang, Yifei Cheng, Shu Zhang, Jia Fan, Qiang Gao
Liver International.2022; 42(9): 2029. CrossRef
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
Clinical and Molecular Hepatology.2022; 28(2): 242. CrossRef
ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals
Yinci Zhang, Niandie Cao, Jiafeng Gao, Jiaojiao Liang, Yong Liang, Yinghai Xie, Shuping Zhou, Xiaolong Tang
Journal of Cellular and Molecular Medicine.2022; 26(10): 2777. CrossRef
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Clinical and Molecular Hepatology.2022; 28(2): 207. CrossRef
A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma
Wenmin Hu, Yongmei Shi, Tongqin Han, Caiyun Liu, Xipeng Cao, Guangjun Shi, Wenjing Zhu
Frontiers in Genetics.2022;[Epub] CrossRef
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis
Charlotte E. Costentin, Mélanie Minoves, Sylvain Kotzki, Olivier Farges, Nathalie Goutté, Thomas Decaens, Sébastien Bailly
Liver International.2022; 42(7): 1638. CrossRef
Association of the presence of allergic disease with subsequent risk of liver cancer in a nationwide retrospective cohort among Koreans
Ji Ah Kim, Sun Jae Park, Seulggie Choi, Jooyoung Chang, Seogsong Jeong, Joseph C.Ahn, Gyeongsil Lee, Joung Sik Son, Sang Min Park
Scientific Reports.2022;[Epub] CrossRef
Impact of discriminant factors on the comfort-care of nurses caring for trans-arterial chemoembolisation patients
Myoung Soo Kim, Ju-Yeon Uhm
Supportive Care in Cancer.2022; 30(9): 7773. CrossRef
Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development
Jong-In Chang, Dong Hyun Sinn, Woo Kyoung Jeong, Jeong Ah Hwang, Ho Young Won, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung-Woon Paik
Scandinavian Journal of Gastroenterology.2022; 57(12): 1470. CrossRef
Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
Journal of Korean Medical Science.2022;[Epub] CrossRef
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
Eun Ae Kang, Jae Hee Cheon
Gut and Liver.2022; 16(4): 501. CrossRef
Risk Association of Liver Cancer and Hepatitis B with Tree Ensemble and Lifestyle Features
Eunji Koh, Younghoon Kim
International Journal of Environmental Research and Public Health.2022; 19(22): 15171. CrossRef
Anti-Liver Cancer Activity of a New Compound Extracted from Populus pruinosa and Phylogenetic Analysis
Hong Liu, Nan Wu
Science of Advanced Materials.2022; 14(5): 971. CrossRef
Liver Diseases in South Korea: A Pulse Check of the Public’s Knowledge, Awareness, and Behaviors
Hye Won Lee, Myunghwa Kim, Jin Youn, Shikha Singh, Sang Hoon Ahn
Yonsei Medical Journal.2022; 63(12): 1088. CrossRef
Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer
Zhenyun Cheng, Yan Guo, Jingjing Sun, Lei Zheng
Scientific Reports.2022;[Epub] CrossRef
Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211. CrossRef
Analysis of Hepatitis C Virus Genotypes and RNA Quantitative Values in Cheonan, Republic of Korea from 2007 to 2016
Bishguurmaa Renchindorj, Bo Kyeung Jung, Joowon Park
Microbiology and Biotechnology Letters.2022; 50(3): 422. CrossRef
Prescription Opioid Misuse in Older Adult Surgical Patients
Chin Hwa Dahlem, Ty S. Schepis, Sean Esteban McCabe, Aaron L. Rank, Luisa Kcomt, Vita V. McCabe, Terri Voepel-Lewis
Journal of Addictions Nursing.2022; 33(4): 218. CrossRef
Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: A national population‐based cohort study
Seawon Hwang, Yong‐Moon Park, Kyung‐Do Han, Jae‐Seung Yun, Seung‐Hyun Ko, Yu‐Bae Ahn, Jae Hyun Han
International Journal of Cancer.2021; 148(5): 1144. CrossRef
Opioid-involved prescription drug misuse and poly-prescription drug misuse in U.S. older adults
Ty S. Schepis, Jason A. Ford, Linda Wastila, Sean Esteban McCabe
Aging & Mental Health.2021; 25(12): 2365. CrossRef
Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child–Pugh Class: A Nationwide Cohort Analysis in South Korea
Sunmin Park, Chai Hong Rim, Young Kul Jung, Won Sup Yoon, Alessandro Granito
Canadian Journal of Gastroenterology and Hepatology.2021;[Epub] CrossRef
Addition of liver stiffness enhances the predictive accuracy of the PAGE‐B model for hepatitis B‐related hepatocellular carcinoma
Hye Yeon Chon, Han Ah Lee, Sang Jun Suh, Jung Il Lee, Byung Seok Kim, In Hee Kim, Chang Hyeong Lee, Byoung Kuk Jang, Hyun Woong Lee, Jae Seok Hwang, Chang Hun Lee, Jin‐Woo Lee, Jung Hwan Yu, Yeon Seok Seo, Hyung Joon Yim, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2021; 53(8): 919. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study
Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini
PLOS ONE.2021; 16(2): e0246143. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
Jihye Lim, Kyung Won Kim, Yousun Ko, Il-Young Jang, Yung Sang Lee, Young-Hwa Chung, Han Chu Lee, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Jonggi Choi, Danbi Lee
BMC Cancer.2021;[Epub] CrossRef
Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma
Hyo-Jung Cho, Jae-Youn Cheong
International Journal of Molecular Sciences.2021; 22(15): 8011. CrossRef
Does low income effects 5-year mortality of hepatocellular carcinoma patients?
Dong Jun Kim, Ji Won Yoo, Jong Wha Chang, Takashi Yamashita, Eun-Cheol Park, Kyu-Tae Han, Seung Ju Kim, Sun Jung Kim
International Journal for Equity in Health.2021;[Epub] CrossRef
Current Status of Therapeutic Choice and Feasibility for Patients with Hepatocellular Carcinoma Aged ≥ 70 Years: A Nationwide Cancer Registry Analysis
Seoung Yoon Rho, Hyun Woong Lee, Do Young Kim, Kyung Sik Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 321. CrossRef
Disparities in Liver Cancer Surveillance Among People With Disabilities
Jae Youn Seo, Dong Wook Shin, Su Jong Yu, Jin Hyung Jung, Kyungdo Han, In Young Cho, So Young Kim, Kui Son Choi, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Journal of Clinical Gastroenterology.2021; 55(5): 439. CrossRef
Predicting survival time of Korean hepatocellular carcinoma patients using the Cox proportional hazards model: a retrospective study based on big data analysis
Yujin Kwon, Jae Ri Kim, Young Mok Park, Byung Kwan Choi, Choongrak Kim, Hae Young Kim, Myunghee Yoon
European Journal of Gastroenterology & Hepatology.2021; 33(7): 1001. CrossRef
Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B
Hye Yeon Chon, Jae Seung Lee, Hye Won Lee, Ho Soo Chun, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Hepatology Research.2021; 51(4): 406. CrossRef
Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study
Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Yoosoo Chang, Seungho Ryu, Di Zhao, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
American Journal of Gastroenterology.2021; 116(2): 329. CrossRef
Structural characterization and anti-liver cancer activity of two Cu(II) coordination polymers
Yu Wu, Ying Liu, Peng Mao, Guo-Feng Ma, Wen Xue, Wei-Dong Tang
Inorganic and Nano-Metal Chemistry.2021; : 1. CrossRef
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
Hepatology International.2021; 15(6): 1328. CrossRef
Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis
Jianfeng Wang, Xiaogang Li
European Journal of Gastroenterology & Hepatology.2021; 33(12): 1603. CrossRef
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
European Journal of Internal Medicine.2021; 89: 48. CrossRef
Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
Korean Journal of Community Nutrition.2021; 26(3): 211. CrossRef
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
Clinical Cancer Research.2021; 27(3): 713. CrossRef
Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma
Moon Haeng Hur, Jeong-Hoon Lee, Ju Yeon Kim, Ji Hoon Hong, Min Kyung Park, Hee Jin Cho, Na Ryung Choi, Jihye Kim, Minseok Albert Kim, Joon Yeul Nam, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Dong Ho Lee, Jeong Min Lee, Suk Kyun Hong, Nam-Joon Yi,
Cancers.2021; 13(23): 6009. CrossRef
Hepatocellular carcinoma statistics in South Korea
Young Eun Chon, Soung Won Jeong, Dae Won Jun
Clinical and Molecular Hepatology.2021; 27(3): 512. CrossRef
Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study
Chansik An, Jong Won Choi, Hyung Soon Lee, Hyunsun Lim, Seok Jong Ryu, Jung Hyun Chang, Hyun Cheol Oh
BMC Cancer.2021;[Epub] CrossRef
Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study
Jeong-Ju Yoo, Eun Ju Cho, Kyungdo Han, Soo Seong Heo, Bo-Yeon Kim, Dong Wook Shin, Su Jong Yu
Cancer Epidemiology, Biomarkers & Prevention.2021; 30(5): 974. CrossRef
Prognosis of hepatocellular carcinoma metastasizing to the oral cavity
Jun-Hee Hong, Keonmo Lee, Jinhong Kim, Kang-Min Ahn
Maxillofacial Plastic and Reconstructive Surgery.2021;[Epub] CrossRef
Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC
Hyo Jung Cho, Geum Ok Baek, Moon Gyeong Yoon, Hye Ri Ahn, Ju A Son, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Diagnostics.2021; 11(7): 1221. CrossRef
Curcumin Nanoparticles Inhibit Liver Cancer by Inhibiting Angiogenesis
Xiemin Dong, Yuyun Tong
Science of Advanced Materials.2021; 13(10): 1878. CrossRef
Changing etiology of hepatocellular carcinoma
Ryosuke Tateishi, Kazuhiko Koike
Journal of Gastroenterology.2020; 55(1): 125. CrossRef
International trends in hepatocellular carcinoma incidence, 1978–2012
Jessica L. Petrick, Andrea A. Florio, Ariana Znaor, David Ruggieri, Mathieu Laversanne, Christian S. Alvarez, Jacques Ferlay, Patricia C. Valery, Freddie Bray, Katherine A. McGlynn
International Journal of Cancer.2020; 147(2): 317. CrossRef
RETRACTED: Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines
Xue Yu, Yu Wang, Shujun Tao, Shulun Sun
Experimental and Molecular Pathology.2020; 112: 104349. CrossRef
Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma
Sunmin Park, Jinhong Jung, Byungchul Cho, So Yeon Kim, Sung‐Cheol Yun, Young‐Suk Lim, Han Chu Lee, Jongmoo Park, Jin‐hong Park, Jong Hoon Kim, Sang Min Yoon
Journal of Gastroenterology and Hepatology.2020; 35(11): 1953. CrossRef
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong Park
Immune Network.2020;[Epub] CrossRef
Prescription Drug Misuse: Taking a Lifespan Perspective
Ty S Schepis, Dalton L Klare, Jason A Ford, Sean Esteban McCabe
Substance Abuse: Research and Treatment.2020;[Epub] CrossRef
The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment
Young Youn Cho, Su Jong Yu, Jung-Ju Yoo, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Kyoung Wan Yoon, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon
Journal of Clinical Gastroenterology.2020; 54(4): 370. CrossRef
A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea
Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn
Journal of Liver Cancer.2020; 20(1): 53. CrossRef
Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
Ju Hyun Shim
Clinical and Molecular Hepatology.2020; 26(2): 183. CrossRef
An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia
Hye W. Lee, Soo Y. Park, Myeongjee Lee, Eun J. Lee, Jinae Lee, Seung U. Kim, Jun Y. Park, Do Y. Kim, Sang H. Ahn, Beom K. Kim
Liver International.2020; 40(7): 1736. CrossRef
Sex-dependent effects of estrogen pellets in human liver cancer xenograft models
Sungryong Oh, Kiheon Choi, Kyoung Mee Kim, Joohee Jung
Toxicological Research.2020; 36(2): 109. CrossRef
Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization
Jae Seung Lee, Han Ah Lee, Mi Young Jeon, Tae Seop Lim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Soon Ho Um, Kwang-Hyub Han, Yeon Seok Seo, Seung Up Kim
European Journal of Gastroenterology & Hepatology.2020; 32(6): 739. CrossRef
Selenium mitigates cadmium-induced crosstalk between autophagy and endoplasmic reticulum stress via regulating calcium homeostasis in avian leghorn male hepatoma (LMH) cells
Cong Zhang, Li-Li Wang, Chang-Yu Cao, Nan Li, Milton Talukder, Jin-Long Li
Environmental Pollution.2020; 265: 114613. CrossRef
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
Aisling Barry, Smith Apisarnthanarax, Grainne M O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young-Suk Lim, John Bridgewater, Brian Davidson, Marta Scorsetti, Luigi Solbiati, Adam Diehl, Pablo Munoz Schuffenegger, Jonathan G Sha
The Lancet Gastroenterology & Hepatology.2020; 5(8): 765. CrossRef
Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim
Hepatology Communications.2020; 4(7): 1073. CrossRef
Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Changhoon Yoo, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi
Cancers.2020; 12(7): 1968. CrossRef
Biological significance of piRNA in liver cancer: a review
Jiamin Xu, Xi Yang, Qing Zhou, Jing Zhuang, Shuwen Han
Biomarkers.2020; 25(6): 436. CrossRef
Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score
Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
International Journal of Epidemiology.2020; 49(5): 1562. CrossRef
Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index
Maki Tobari, Etsuko Hashimoto
Gut and Liver.2020; 14(5): 537. CrossRef
Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(9): 2527. CrossRef
A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy
Seung Up Kim, Yong Eun Chon, Yeon Seok Seo, Hye Won Lee, Han Ah Lee, Mi Na Kim, In Kyung Min, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Won Young Tak, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2020; 27(12): 1352. CrossRef
Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study
Young-Sun Lee, Young K. Jung, Ji H. Kim, Sung B. Cho, Do Y. Kim, Moon Y. Kim, Hyung J. Kim, Yeon S. Seo, Ki T. Yoon, Young M. Hong, Jeong-Hoon Lee, Hyun W. Lee, Hyung J. Yim, Byoung K. Jang, Eun S. Jang, Jae Y. Jang, Sang Y. Hwang
European Journal of Cancer.2020; 140: 19. CrossRef
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clinical and Molecular Hepatology.2020; 26(4): 516. CrossRef
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clinical and Molecular Hepatology.2020; 26(4): 506. CrossRef
Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry
Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
Journal of Liver Cancer.2020; 20(2): 135. CrossRef
Anthocyanins Derived from Vitis coignetiae Pulliat Contributes Anti-Cancer Effects by Suppressing NF-κB Pathways in Hep3B Human Hepatocellular Carcinoma Cells and In Vivo
Min Jeong Kim, Anjugam Paramanantham, Won Sup Lee, Jeong Won Yun, Seong Hwan Chang, Dong Chul Kim, Hyeon Soo Park, Yung Hyun Choi, Gon Sup Kim, Chung Ho Ryu, Sung Chul Shin, Soon Chan Hong
Molecules.2020; 25(22): 5445. CrossRef
Loss of miR-100 and miR-125b results in cancer stem cell properties through IGF2 upregulation in hepatocellular carcinoma
Hyang Sook Seol, Yoshimitsu Akiyama, San-Eun Lee, Shu Shimada, Se Jin Jang
Scientific Reports.2020;[Epub] CrossRef
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2020; Volume 7: 403. CrossRef
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong, Oh Sang Kwon, Jong Eun Yeon, Bo Hyun Kim, Jaeseok Hwang
Journal of Hepatology.2019; 70(4): 684. CrossRef
Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients
Dong Hyun Sinn, Gyu-Seong Choi, Hee Chul Park, Jong Man Kim, Honsoul Kim, Kyoung Doo Song, Tae Wook Kang, Min Woo Lee, Hyunchul Rhim, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Woo Kyoung Jeong, Seong Hyun Kim, Jeong Il Yu, Sang Yun Ha, Su Jin Lee, Ho Yeon
PLOS ONE.2019; 14(1): e0210730. CrossRef
Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization
Hae Lim Lee, Jeong Won Jang, Sung Won Lee, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon
Scientific Reports.2019;[Epub] CrossRef
Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study
Dong Hyun Sinn, Danbee Kang, Minwoong Kang, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
BMC Cancer.2019;[Epub] CrossRef
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park
Cancers.2019; 11(4): 509. CrossRef
Combination Therapy of Angiotherapy, Radiation Therapy, and Radiofrequency Ablation for Pulmonary Metastasis of Hepatocellular Carcinoma Accompanied by Nontuberculous Mycobacteria
Sang Hyun Park, Seul Ki Kim, Ji Hye Kim, Seokgyo Seo, Hyun Pyo Hong, Soo-Youn Ham, Byung Ik Kim
Journal of Liver Cancer.2019; 19(1): 79. CrossRef
External validation of the modified PAGE‐B score in Asian chronic hepatitis B patients receiving antiviral therapy
Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Beom Kyung Kim
Liver International.2019; 39(9): 1624. CrossRef
Updated Treatment of Chronic Hepatitis B
Eileen L. Yoon, Hyung Joon Yim
The Korean Journal of Medicine.2019; 94(3): 252. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma
Gi-Ae Kim, Ha Il Kim, Seheon Chang, Jihyun An, Danbi Lee, Han Chu Lee, Seungbong Han, Ju Hyun Shim
American Journal of Clinical Oncology.2019; 42(7): 555. CrossRef
Comparison of 2 curative treatment options for very early hepatocellular carcinoma
Tae Hyung Kim, Jung Mi Chang, Soon Ho Um, Heejung Jee, Yoo Ra Lee, Han Ah Lee, Sun Young Yim, Na Yeon Han, Jae Min Lee, Hyuk Soon Choi, Eun Sun Kim, Young-Dong Yu, Bora Keum, Min Ju Kim, Hyunggin An, Beom Jin Park, Yeon Seok Seo, Dong-Sik Kim, Hyung Joon
Medicine.2019; 98(26): e16279. CrossRef
Changes in hepatitis B antibody status after chemotherapy in children with acute lymphoblastic leukemia
Young Bae Choi, Na Hee Lee, Eun Sang Yi, Yae‐Jean Kim, Hong Hoe Koo
Pediatric Blood & Cancer.2019;[Epub] CrossRef
Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals
Hye Won Lee, Seung Up Kim, Jun Yong Park, Oidov Baatarkhuu, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
Clinical and Translational Gastroenterology.2019; 10(6): e00036. CrossRef
The epidemiology of hepatitis B virus infection in Korea
Sun Young Yim, Ji Hoon Kim
The Korean Journal of Internal Medicine.2019; 34(5): 945. CrossRef
Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation
Chang Gon Kim, Hyun Woong Lee, Hye Jin Choi, Jung Il Lee, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Han Sang Kim, Kyung Hwan Kim, Seong Jin Choi, Yongun Kim, Kwan Sik Lee, Gyoung Min Kim, Man Deuk Kim, Jong Yoo
Cancer Medicine.2019; 8(11): 5023. CrossRef
Effective therapeutic options for elderly patients with hepatocellular carcinoma
Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Deuck Hwa Kim, Seyoun Byun, Jin-Woo Lee
Medicine.2019; 98(30): e16150. CrossRef
Hepatitis B virus DNA levels and overall survival in hepatitis B‐related hepatocellular carcinoma patients with low‐level viremia
Tae‐Se Kim, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Journal of Gastroenterology and Hepatology.2019; 34(11): 2028. CrossRef
Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma
Hye Kyong Park, Sang Soo Lee, Chang Bin Im, Changjo Im, Ra Ri Cha, Wan Soo Kim, Hyun Chin Cho, Jae Min Lee, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok-Jae Lee
BMC Cancer.2019;[Epub] CrossRef
Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study
Young Chang, Yuri Cho, Jeong-Hoon Lee, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Hyun Sinn, Bo Hyun Kim, Seoung Hoon Kim, Nam-Joon Yi, Kwang-Woong Lee, Jong Man Kim, Joong-Won Park, Yoon Jun Kim, Jung-Hwan Yoon, Jae-Won Joh, Kyung-Suk Suh
Cancers.2019; 11(9): 1295. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Prognostic factors in hepatocellular carcinoma patients with bone metastases
Sungmin Kim, Youngmin Choi, Dong-Won Kwak, Hyung Sik Lee, Won-Joo Hur, Yang Hyun Baek, Sung Wook Lee
Radiation Oncology Journal.2019; 37(3): 207. CrossRef
Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database
Jae Seung Lee, In Rae Cho, Hye Won Lee, Mi Young Jeon, Tae Seop Lim, Oidov Baatarkhuu, Do Young Kim, Kwang-Hyub Han, Jun Yong Park
Cancer Research and Treatment.2019; 51(4): 1347. CrossRef
Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study
Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee
PLOS ONE.2019; 14(10): e0223678. CrossRef
Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization
Soon Young Ko, Won Hyeok Choe
The Korean Journal of Internal Medicine.2019; 34(6): 1210. CrossRef
Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma
Dong Wook Jekarl, Seungok Lee, Jung Hyun Kwon, Soon Woo Nam, Myungshin Kim, Yonggoo Kim, Jeong Won Jang, William B. Coleman
PLOS ONE.2019; 14(11): e0224318. CrossRef
Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma
Hyun Woong Lee
The Korean Journal of Gastroenterology.2019; 74(5): 251. CrossRef
Updates on Cancer Epidemiology in Korea, 2018
Sun-Seog Kweon
Chonnam Medical Journal.2018; 54(2): 90. CrossRef
Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
Journal of Korean Medical Science.2018;[Epub] CrossRef

Cite

CITE

export

Copy Download

Format
XML Download

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Epidemiology of liver cancer in South Korea

Clin Mol Hepatol. 2018;24(1):1-9. Published online December 18, 2017

DOI: https://doi.org/10.3350/cmh.2017.0112

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
bib — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Epidemiology of liver cancer in South Korea

Clin Mol Hepatol. 2018;24(1):1-9. Published online December 18, 2017

DOI: https://doi.org/10.3350/cmh.2017.0112

Figure

Epidemiology of liver cancer in South Korea

Figure 1. Trends in primary liver cancer incidence. Dark grey columns and light grey columns represent the number of male and female incident cases, respectively (left axis). Solid symbols indicate crude incidence rates and hollow symbols indicate age-standardized incidence rates (right axis).

Figure 2. Age-specific incidence of liver cancer. (A) Dark grey columns and light grey columns represent the number of male and female incident cases in 2014, respectively (left axis). The black solid line indicates the age-specific incidence rates while the dark grey dashed line and light grey dotted line indicate age-specific incidence rates in males and females, respectively (right axis). (B) Light grey columns and dark grey columns represent the number of cases diagnosed in 2005 and 2014, respectively (left axis). Solid symbols and hollow symbols indicate age-specific incidence rates in 2005 and 2014, respectively (right axis).

Figure 3. Crude and age-standardized incidence of liver cancer by region. Light grey columns and dark grey columns represent crude incidence rates in 2005 and 2014, respectively. Solid symbols and hollow symbols indicate age-standardized incidence rates in 2005 and 2014, respectively. SU, Seoul; BS, Busan; DG, Daegu; IC, Incheon; GJ, Gwangju; DJ, Daejeon; US, Ulsan; SJ, Sejong; GG, Gyeonggi-do; GW, Gangwon-do; CB, Chungcheongbuk-do; CN, Chungcheongnam-do; JB, Jeollabuk-do; JN, Jeollanam-do; GB, Gyeongsangbuk-do; GN, Gyeongsangnam-do; JJ, Jeju-do.

Figure 4. Trends in prevalence of primary liver cancer. Dark grey columns and light grey columns represent the number of male and female prevalent cases, respectively (left axis). Solid symbols indicate crude prevalence rates and hollow symbols indicate age-standardized prevalence rates (right axis).

Figure 5. Age-specific prevalence of liver cancer. (A) Dark grey columns and light grey columns represent the number of male and female prevalent cases in 2014, respectively (left axis). The black solid line indicates the age-specific prevalence while the dark grey dashed line and light grey dotted line indicate age-specific prevalence rates of males and females, respectively (right axis). (B) Light grey columns and dark grey columns represent the number of prevalent cases in 2010 and 2014, respectively (left axis). Solid symbols and hollow symbols indicate age-specific prevalence rates in 2010 and 2014, respectively (right axis).

Figure 6. Trends in primary liver cancer survival. Light grey columns and dark grey columns denote 5-year relative survival rates (the ratio of survival rates of individuals who were diagnosed with liver cancer to those who were not) and 10-year relative survival rates, respectively.

Figure 7. Trends in liver cancer mortality rates. Dark grey columns and light grey columns represent the number of male and female mortality cases from liver cancer, respectively (left axis). Solid symbols indicate crude mortality rates and hollow symbols indicate age-standardized mortality rates (right axis).

Figure 8. Age distribution of cancer mortality. The upper bar represents percentages of mortality cases from all-sites cancers and the lower bar represents those of mortality cases from liver cancer according to the ages.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Epidemiology of liver cancer in South Korea

	Number	Period	Data source	Age/Sex	Etiology	Child-Turcotte-Pugh class	BCLC stage	Treatment
Kim, et al. [7] (2012)	1717	2003–2008	Single hospital	57.0 yr (median)	HBV (72.1%)	A (77.1%)	0 (9.8%)
				Male (80.3%)	HCV (10.4%)	B (19.7%)	A (30.6%)
					Alcohol (2.4%)	C (3.2%)	B (19.4%)
							C (35.4%)
							D (4.8%)
Kwak, et al. [9] (2014)	1972	2004–2009	Single hospital	56.0 yr (median)	HBV (74.6%)	A (81.6%)	0 (4.7%)	Resection (1.5%)
				Male (81.6%)	HCV (9.3%)	B (16.7%)	A (19.8%)	Local ablation (3.5%)
					Alcohol (7.4%)	C (1.7%)	B (9.3%)	Transplantation (1.5%)
							C (64.4%)	Transarterial therapy (58.3%)
							D (1.8%)	Radiotherapy (5.0%)
								Systemic therapy (5.7%)
								Supportive care (7.4%)
Lee, et al. [10] (2017)	2211	2004–2013	Three hospitals	58.3 yr	HBV (68.9%)	A (59.3%)	0 (13%)	Resection (13.4%)
				Male (79.5%)	HCV (11.6%)	B (29.7%)	A (33%)	Local ablation (19.2%)
					Alcohol (10.9%)	C (11.0%)	B (12%)	Transplantation (0.5%)
							C (29%)	Transarterial therapy (46.0%)
							D (13%)	Systemic therapy (4.7%)
							D (13%)	Supportive care (16.1%)
Kim, et al. [8] (2017)	4515	2003–2005	Population-based national cancer registry	57.2 yr	HBV (62.5%)	A (64.2%)	0 (7.2%)	Resection (9.7%)
				Male (81.1%)	HCV (9.9%)	B (26.9%)	A (47.0%)	Local ablation (7.1%)
						C (8.8%)	B (10.4%)	Transplantation (0.7%)
							C (26.6%)	Transarterial therapy (53.4%)
							D (8.8%)	Systemic therapy (0.8%)
								Radiotherapy (1.1%)
								Supportive care (27.2%)
	4582	2008–2010		59.4 yr	HBV (62.2%)	A (71.6%)	0 (8.1%)	Resection (15.6%)
				Male (77.9%)	HCV (10.4%)	B (23.4%)	A (41.5%)	Local ablation (11.0%)
						C (5.0%)	B (11.3%)	Transplantation (0.7%)
							C (33.0%)	Transarterial therapy (46.1%)
							D (6.2%)	Systemic therapy (4.1%)
								Radiotherapy (1.3%)
								Supportive care (21.2%)

Table 1. Clinical characteristics of patients diagnosed with hepatocellular carcinoma

HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer.

Articles

Page Path

Epidemiology of liver cancer in South Korea

Full Article

ABSTRACT

INTRODUCTION

INCIDENCE OF LIVER CANCER IN KOREA

PREVALENCE OF LIVER CANCER IN KOREA

ETIOLOGY OF HCC IN KOREA

NATURAL HISTORY AND MORTALITY OF HCC IN KOREA

CONCLUSIONS

FOOTNOTES

Abbreviations

REFERENCES

Figure & Data

References

Citations

CITE

Download Citation

Format:

Include:

Figure

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Table 1.

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS